(IN BRIEF) Eckert & Ziegler SE and Molecular Partners AG have entered into a partnership to develop and potentially manufacture DARPin-based radiopharmaceutical therapies for cancer treatment. Eckert & Ziegler will provide development services for Radio-DARPins using Actinium-225 and Lutetium-177 isotopes, … Read the full press release
Posted in Berlin, Business, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged Actinium-225, alpha emitters, Berlin development laboratory, biotechnology collaboration, DARPin technology, Eckert & Ziegler and Molecular Partners Collaborate on DARPin-Based Radiopharmaceutical Development for Targeted Cancer Therapy, Eckert & Ziegler Expands Radiopharmaceutical Development Capabilities Through Partnership with Molecular Partners, Eckert & Ziegler SE, Harald Hasselmann, isotope technology, Lutetium-177, Molecular Partners AG, nuclear medicine, oncology therapeutics, Radio-DARPins, radiochemistry, radiolabeled therapeutics, radiopharmaceuticals, targeted cancer therapy, TecDAX
(IN BRIEF) Novartis has announced plans to establish a 46,000-square-foot radioligand therapy manufacturing facility in Denton, Texas, with operations expected to begin in 2028. The new site will expand the company’s U.S. manufacturing network and support growing demand for targeted … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Switzerland
Tagged advanced manufacturing, bioengineering jobs, cancer treatment manufacturing, Dallas Fort Worth biotech, Denton Texas, Greg Abbott, Novartis, Novartis Expands Radioligand Therapy Network with New Manufacturing Site in Denton Texas, Novartis Strengthens US Radioligand Therapy Production with Planned Texas Manufacturing Investment, nuclear medicine, oncology pipeline, pharmaceutical manufacturing, radioligand therapy RLT, radiopharmaceuticals, targeted radiation therapy, US investment program, Vas Narasimhan
(IN BRIEF) Eckert & Ziegler and the Nuclear Physics Institute of the Czech Academy of Sciences have scaled up production of the critical medical isotope Actinium-225, moving from development into larger-scale manufacturing at facilities in Řež and Braunschweig. The expansion … Read the full press release
Posted in Business, Czech Republic, Financial, Germany, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged Actinium-225, Braunschweig production, CDMO services, Eckert & Ziegler, Gallium-68, isotope supply chain, Lutetium-177, nuclear medicine, Nuclear Physics Institute Czech Academy of Sciences, oncology innovation, Partnership Advances Commercial Production of Actinium-225 for Next Generation Nuclear Medicine Applications, radioisotope production, radiopharmaceuticals, Řež facility, targeted alpha therapy, TecDAX listed company, Yttrium-90
(IN BRIEF) Eckert & Ziegler successfully hosted the 3rd annual Boston Radionuclide Theranostics Forum, bringing together industry leaders to discuss radionuclide theranostics’ role in transforming precision oncology. The event featured expert presentations on advancements in radiopharmaceuticals, clinical development challenges, and … Read the full press release
Posted in Berlin, Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Technology
Tagged Boston Radionuclide Theranostics Forum, clinical development, Dr. Harald Hasselmann, Eckert & Ziegler, German American Business Council, Industry innovation, Morrison Foerster, nuclear medicine, patient access, precision oncology, radionuclide theranostics, radiopharmaceutical community, radiopharmaceuticals, radiotherapy, Solomon Partners
(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?